Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Less Equipment Would Be Stocked At Ambulatory Surgical Centers Under CMS Proposal

This article was originally published in The Gray Sheet

Executive Summary

A government plan to slash regulatory burdens for health care providers would, among other changes, reduce the amount and type of emergency medical equipment required at ambulatory surgical centers.

You may also be interested in...



Device Makers Identify More FDA Regulations Worth Revising

Device makers have proposed several regulations that FDA should revisit to lighten manufacturers' burdens as part of the agency's ongoing regulatory review.

Device Innovation: Report Paints Dire Picture; Prez, FDA Take "Positive" Steps

Last week started off with a particularly negative appraisal for the prospects of continued U.S. leadership in medical device innovation under current policies, but it was followed by two developments that almost appeared as corrective responses by the federal government.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

UsernamePublicRestriction

Register

MT030660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel